Fig. 3

Clinical course of the patient after nivolumab therapy. The patient’s creatine phosphokinase level increased to > 1000 at 22 days after nivolumab administration, when treatment with prednisolone (30 mg/body per day) was initiated. Because his creatine phosphokinase level did not improve, steroid pulse therapy and intravenously administered immunoglobulin were initiated. His creatine phosphokinase level subsequently decreased markedly and his symptoms improved. After tapering prednisolone to 30 mg/day, tacrolimus was applied to maintain the improved status. CK creatine phosphokinase, IVIg intravenous immunoglobulin, mPSL methylprednisolone, PSL prednisolone, TAC tacrolimus